TW200800985A - New imidazopyridine derivatives - Google Patents
New imidazopyridine derivativesInfo
- Publication number
- TW200800985A TW200800985A TW095137259A TW95137259A TW200800985A TW 200800985 A TW200800985 A TW 200800985A TW 095137259 A TW095137259 A TW 095137259A TW 95137259 A TW95137259 A TW 95137259A TW 200800985 A TW200800985 A TW 200800985A
- Authority
- TW
- Taiwan
- Prior art keywords
- antagonists
- inhibitors
- treatment
- pathological condition
- agonists
- Prior art date
Links
- 125000004857 imidazopyridinyl group Chemical class N1C(=NC2=C1C=CC=N2)* 0.000 title 1
- 239000005557 antagonist Substances 0.000 abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 2
- 108050000203 Adenosine receptors Proteins 0.000 abstract 1
- 102000009346 Adenosine receptors Human genes 0.000 abstract 1
- 101150078577 Adora2b gene Proteins 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010006482 Bronchospasm Diseases 0.000 abstract 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 abstract 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 abstract 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 abstract 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 102100037346 Substance-P receptor Human genes 0.000 abstract 1
- 102000000551 Syk Kinase Human genes 0.000 abstract 1
- 108010016672 Syk Kinase Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000007885 bronchoconstriction Effects 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229960001334 corticosteroids Drugs 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200502433A ES2274712B1 (es) | 2005-10-06 | 2005-10-06 | Nuevos derivados imidazopiridina. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200800985A true TW200800985A (en) | 2008-01-01 |
Family
ID=36295447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095137259A TW200800985A (en) | 2005-10-06 | 2006-10-05 | New imidazopyridine derivatives |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7855202B2 (https=) |
| EP (1) | EP1931666A1 (https=) |
| JP (1) | JP2009510152A (https=) |
| KR (1) | KR20080050475A (https=) |
| CN (1) | CN101326181A (https=) |
| AR (1) | AR055676A1 (https=) |
| AU (1) | AU2006299028A1 (https=) |
| CA (1) | CA2624879A1 (https=) |
| EC (1) | ECSP088343A (https=) |
| ES (1) | ES2274712B1 (https=) |
| IL (1) | IL190336A0 (https=) |
| NO (1) | NO20082121L (https=) |
| PE (1) | PE20070706A1 (https=) |
| RU (1) | RU2008117329A (https=) |
| TW (1) | TW200800985A (https=) |
| UY (1) | UY29836A1 (https=) |
| WO (1) | WO2007039297A1 (https=) |
| ZA (1) | ZA200802588B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| ATE543819T1 (de) | 2006-10-19 | 2012-02-15 | Signal Pharm Llc | Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit |
| ES2303776B1 (es) * | 2006-12-29 | 2009-08-07 | Laboratorios Almirall S.A. | Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b. |
| ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| GEP20125379B (en) | 2007-05-03 | 2012-01-10 | Pfizer Ltd | 2 -pyridine carboxamide derivatives as sodium channel modulators |
| AU2008343813B2 (en) * | 2007-12-19 | 2012-04-12 | Amgen Inc. | Inhibitors of PI3 kinase |
| EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
| EP2294066B9 (en) * | 2008-04-28 | 2015-03-11 | Janssen Pharmaceutica, N.V. | Benzoimidazoles as prolyl hydroxylase inhibitors |
| WO2010133534A1 (en) * | 2009-05-19 | 2010-11-25 | Cellzome Limited | Bicyclic amino substituted compounds as pi3k inhibitors |
| EP2322176A1 (en) | 2009-11-11 | 2011-05-18 | Almirall, S.A. | New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives |
| BR112012032766A2 (pt) | 2010-06-30 | 2019-09-24 | Gilead Sciences Inc | uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonar |
| WO2012033149A1 (ja) * | 2010-09-10 | 2012-03-15 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有するヘテロ環縮合イミダゾール誘導体 |
| AR085942A1 (es) | 2011-04-07 | 2013-11-06 | Gilead Sciences Inc | Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio |
| KR101913619B1 (ko) * | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
| US9273034B2 (en) | 2011-10-25 | 2016-03-01 | Janssen Pharmaceutica Nv | Meglumine salt formulations of 1-(5,6-dichloro-1H-benzo[D]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid |
| JP2015515472A (ja) | 2012-04-06 | 2015-05-28 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害薬 |
| RU2644558C2 (ru) * | 2012-06-19 | 2018-02-13 | Сановьон Фармасьютикалз Инк. | Гетероарильные соединения и способы их применения |
| US9650376B2 (en) | 2013-03-15 | 2017-05-16 | Knopp Biosciences Llc | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators |
| US11175268B2 (en) | 2014-06-09 | 2021-11-16 | Biometry Inc. | Mini point of care gas chromatographic test strip and method to measure analytes |
| US11435340B2 (en) | 2014-06-09 | 2022-09-06 | Biometry Inc. | Low cost test strip and method to measure analyte |
| SI3572405T1 (sl) | 2014-09-12 | 2023-12-29 | Biohaven Therapeutics Ltd. | Amidi benzoimidazol-1,2-il kot aktivatorji kanalov kv 7 |
| ES2580702B1 (es) * | 2015-02-25 | 2017-06-08 | Palobiofarma, S.L. | Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina |
| EP3487407B1 (en) | 2016-07-19 | 2024-10-02 | Biometry Inc. | Methods of and systems for measuring analytes using batch calibratable test strips |
| FI3562487T3 (fi) | 2016-12-29 | 2023-12-14 | Ji Xing Pharmaceuticals Hong Kong Ltd | Metalloentsyymi-inhibiittoriyhdisteitä |
| EP3562306B1 (en) | 2016-12-29 | 2025-02-26 | Ji Xing Pharmaceuticals Hong Kong Limited | Metalloenzyme inhibitor compounds |
| US11312715B2 (en) | 2017-09-28 | 2022-04-26 | Cstone Pharmaceuticals (Suzhou) Co., Ltd. | Fused ring derivative as A2A receptor inhibitor |
| ES2992256T3 (es) * | 2018-05-08 | 2024-12-11 | Nippon Shinyaku Co Ltd | Compuestos de azabencimidazol y producto farmacéutico |
| CA3126224A1 (en) | 2019-01-08 | 2020-07-16 | Corxel Pharmaceuticals Hong Kong Limited | Metalloenzyme inhibitor compounds |
| US20200345725A1 (en) | 2019-01-11 | 2020-11-05 | Omeros Corporation | Methods and Compositions for Treating Cancer |
| WO2021095805A1 (ja) * | 2019-11-13 | 2021-05-20 | 日本新薬株式会社 | 機能性消化管障害及び口腔乾燥症の治療剤及び予防剤 |
| BR112022008571A2 (pt) | 2019-11-13 | 2022-08-09 | Nippon Shinyaku Co Ltd | Composto de azabenzimidazol e medicamento |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9309573D0 (en) * | 1993-05-10 | 1993-06-23 | Merck Sharp & Dohme | Therapeutic agents |
| KR0151816B1 (ko) * | 1994-02-08 | 1998-10-15 | 강박광 | 신규의 치환된 피리딜 이미다졸 유도체 및 그의 제조방법 |
| US5686470A (en) * | 1995-02-10 | 1997-11-11 | Weier; Richard M. | 2, 3-substituted pyridines for the treatment of inflammation |
| US6096748A (en) | 1996-03-13 | 2000-08-01 | Smithkline Beecham Corporation | Pyrimidine compounds useful in treating cytokine mediated diseases |
| AR038955A1 (es) | 1996-12-05 | 2005-02-02 | Amgen Inc | Compuestos de pirimidinona y piridona sustituidos y metodos para su uso |
| ES2304797T3 (es) | 1997-12-19 | 2008-10-16 | Amgen Inc. | Compuestos de piridina y piridazina sustituidos y su uso farmaceutico. |
| KR100581199B1 (ko) | 1998-06-19 | 2006-05-17 | 카이론 코포레이션 | 글리코겐 신타제 키나제 3의 억제제 |
| US6545002B1 (en) | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
| US6841549B1 (en) * | 1999-07-02 | 2005-01-11 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
| EP1208100B1 (en) | 1999-08-31 | 2003-04-02 | Vanderbilt University | Selective antagonists of a2b adenosine receptors |
| CA2400206A1 (en) | 2000-02-17 | 2001-08-23 | Cv Therapeutics, Inc. | Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation |
| JP4064671B2 (ja) | 2000-02-25 | 2008-03-19 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシン受容体モジュレーター |
| KR20070058022A (ko) | 2000-04-26 | 2007-06-07 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 배변을 촉진하는 의약 조성물 |
| JP4251868B2 (ja) * | 2000-08-11 | 2009-04-08 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ２−アミノピリジン化合物および医薬用途 |
| AU2001295026B2 (en) | 2000-09-06 | 2008-04-03 | Novartis Vaccines And Diagnostics, Inc. | Inhibitors of glycogen synthase kinase 3 |
| EP1317450B1 (en) | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| JP4122216B2 (ja) | 2000-09-19 | 2008-07-23 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | ＧＳＫ−３βタンパク質の特徴づけおよびその使用方法 |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| DE60206756T2 (de) * | 2001-06-29 | 2006-07-13 | CV Therapeutics, Inc., Palo Alto | Purin derivate als a2b adenosin rezeptor antagonisten |
| TWI330183B (https=) | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
| US6977300B2 (en) * | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| DK1444233T3 (da) | 2001-11-09 | 2011-10-17 | Gilead Palo Alto Inc | A2B-adenosinreceptorantagonister |
| US20050043315A1 (en) | 2002-01-02 | 2005-02-24 | Hideo Tsutsumi | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them |
| MXPA03008967A (es) | 2002-02-01 | 2004-02-12 | King Pharmaceuticals Res & Dev | Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b. |
| AU2003245700A1 (en) * | 2002-02-12 | 2003-09-04 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| WO2003082191A2 (en) | 2002-03-28 | 2003-10-09 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
| EA200500005A1 (ru) | 2002-06-12 | 2005-06-30 | Байоджен Айдек Ма Инк. | Способ лечения повреждения, вызванного реперфузией после ишемии, с использованием антагонистов рецептора аденозина |
| US20040067955A1 (en) | 2002-09-06 | 2004-04-08 | Fujisawa Pharmaceutical Co. Ltd. | Pyridazinone compound and pharmaceutical use thereof |
| KR20120032574A (ko) | 2002-10-03 | 2012-04-05 | 탈자진 인코포레이티드 | 혈관항상성 유지제 및 그의 사용 방법 |
| KR101312736B1 (ko) | 2003-02-27 | 2013-09-27 | 팔라우 파르마 에스에이 | 피라졸로피리딘 유도체 |
| DE60322748D1 (de) | 2003-05-06 | 2008-09-18 | Cv Therapeutics Inc | Xanthinderivate als a2b-adenosinrezeptorantagonisten |
| ES2557310T3 (es) | 2003-08-25 | 2016-01-25 | Dogwood Pharmaceuticals, Inc. | 8-heteroaril xantinas substituidas |
| ES2229928B1 (es) | 2003-10-02 | 2006-07-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirimidin-2-amina. |
| GB0323138D0 (en) | 2003-10-03 | 2003-11-05 | Chang Lisa C W | Pyrimidines substituted in the 2,4,6 positions and their different uses |
| CA2543644A1 (en) | 2003-10-27 | 2005-05-06 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof |
| CA2544193C (en) | 2003-10-31 | 2012-03-27 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists |
| GB0401336D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| ES2241496B1 (es) * | 2004-04-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridina. |
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| ES2303776B1 (es) | 2006-12-29 | 2009-08-07 | Laboratorios Almirall S.A. | Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b. |
-
2005
- 2005-10-06 ES ES200502433A patent/ES2274712B1/es not_active Expired - Fee Related
-
2006
- 2006-10-03 UY UY29836A patent/UY29836A1/es unknown
- 2006-10-04 PE PE2006001205A patent/PE20070706A1/es not_active Application Discontinuation
- 2006-10-05 RU RU2008117329/04A patent/RU2008117329A/ru not_active Application Discontinuation
- 2006-10-05 AU AU2006299028A patent/AU2006299028A1/en not_active Abandoned
- 2006-10-05 KR KR1020087008297A patent/KR20080050475A/ko not_active Withdrawn
- 2006-10-05 CA CA002624879A patent/CA2624879A1/en not_active Abandoned
- 2006-10-05 AR ARP060104379A patent/AR055676A1/es unknown
- 2006-10-05 JP JP2008533934A patent/JP2009510152A/ja active Pending
- 2006-10-05 US US12/089,050 patent/US7855202B2/en not_active Expired - Fee Related
- 2006-10-05 WO PCT/EP2006/009620 patent/WO2007039297A1/en not_active Ceased
- 2006-10-05 EP EP06806042A patent/EP1931666A1/en not_active Withdrawn
- 2006-10-05 CN CNA2006800371946A patent/CN101326181A/zh active Pending
- 2006-10-05 TW TW095137259A patent/TW200800985A/zh unknown
-
2008
- 2008-03-20 ZA ZA200802588A patent/ZA200802588B/xx unknown
- 2008-03-20 IL IL190336A patent/IL190336A0/en unknown
- 2008-04-03 EC EC2008008343A patent/ECSP088343A/es unknown
- 2008-05-06 NO NO20082121A patent/NO20082121L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200802588B (en) | 2009-09-30 |
| AR055676A1 (es) | 2007-08-29 |
| WO2007039297A1 (en) | 2007-04-12 |
| ES2274712A1 (es) | 2007-05-16 |
| JP2009510152A (ja) | 2009-03-12 |
| RU2008117329A (ru) | 2009-11-20 |
| US7855202B2 (en) | 2010-12-21 |
| UY29836A1 (es) | 2007-04-30 |
| US20080275038A1 (en) | 2008-11-06 |
| ES2274712B1 (es) | 2008-03-01 |
| IL190336A0 (en) | 2009-09-22 |
| KR20080050475A (ko) | 2008-06-05 |
| CN101326181A (zh) | 2008-12-17 |
| CA2624879A1 (en) | 2007-04-12 |
| PE20070706A1 (es) | 2007-09-24 |
| AU2006299028A1 (en) | 2007-04-12 |
| NO20082121L (no) | 2008-07-07 |
| EP1931666A1 (en) | 2008-06-18 |
| ECSP088343A (es) | 2008-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200800985A (en) | New imidazopyridine derivatives | |
| JP5852099B2 (ja) | ある種のアミノ−ピリミジン、その組成物、及びそれを用いるための方法 | |
| KR100849839B1 (ko) | Ｎ-치환된 비-아릴-헤테로사이클릭 ｎｍｄａ/ｎｒ2ｂ 길항제 및 이를 포함하는 약제학적 조성물 | |
| US20260035373A1 (en) | Pyrrolopyrimidine itk inhibitors | |
| EP1664032B1 (en) | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors | |
| EP1711184B1 (en) | (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity | |
| UA87840C2 (ru) | Конденсированные производные пиридина, применимые как антагонисты аденозинового рецептора а2в | |
| KR101542516B1 (ko) | 5,6-다이하이드로-1ｈ-파이리딘-2-온 화합물 | |
| CA2671982A1 (en) | Methods of using mek inhibitors | |
| US20080255203A1 (en) | Heterocyclic compounds and their methods of use | |
| AU2020319879A1 (en) | Deuterated MK2 pathway inhibitors and methods of using the same | |
| AU2020265828A1 (en) | Substituted pyrrolopyridines as JAK inhibitors | |
| HRP980434A2 (en) | 4-AMINOPYRROLE (3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | |
| WO1998025617A1 (en) | Substituted aryl piperazines as modulators of chemokine receptor activity | |
| WO2001002400A1 (en) | Fused imidazole compounds and remedies for diabetes mellitus | |
| AU2005313348A1 (en) | 2,4 (4,6) pyrimidine derivatives | |
| TW200728299A (en) | New pyrazine derivatives | |
| JP4390454B2 (ja) | チエノ（３，２−ｄ）ピリミジンおよびフラノ（３，２−ｄ）ピリミジン、ならびにそれらのプリン作動性レセプターアンタゴニストとしての使用 | |
| AU2008208801A1 (en) | Purine derivatives | |
| KR20050044600A (ko) | [1,2,4]-트리아졸 바이사이클릭 아데노신 Ａ2ａ 수용체길항제 | |
| CN118852118A (zh) | 抑制酪氨酸激酶活性的化合物和包括其的药物组合物 | |
| CA2521396A1 (en) | Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5 | |
| US20220235043A1 (en) | Substituted sulfonamide pyrrolopyridines as jak inhibitors | |
| JP2010527999A (ja) | ＰＫＣ−θ阻害剤としてのプリノン類および１Ｈ−イミダゾピリジノン類 | |
| TWI710554B (zh) | 新穎苯并咪唑化合物及其醫藥用途 |